A double-blind, randomized, placebo-controlled, Phase I/II Study evaluating the safety, immunogenicity and clinical activity of neoadjuvant treatment with WT1-A10 + AS15 Antigen-Specific Cancer Immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II or III breast cancer

Trial Profile

A double-blind, randomized, placebo-controlled, Phase I/II Study evaluating the safety, immunogenicity and clinical activity of neoadjuvant treatment with WT1-A10 + AS15 Antigen-Specific Cancer Immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II or III breast cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs GSK 2302024A (Primary) ; Antineoplastics; Aromatase inhibitors; Trastuzumab
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use
  • Acronyms INDUCT; NEOADJ
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 24 Sep 2014 Status changed from recruiting to discontinued, as per ClinicalTrials.gov record.
    • 29 Apr 2014 New source identified and integrated (M.D. Anderson Cancer Center: 2013-0418).
    • 02 Aug 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top